Willeke M C Van Roon-Mom

List of Publications by Year
in descending order

84 papers	4,116 citations	147801 31 h-index	118850 62 g-index
86 all docs	86 docs citations	86 times ranked	5914 citing authors

#	Article	IF	Citations
1	Human Neuroblasts Migrate to the Olfactory Bulb via a Lateral Ventricular Extension. Science, 2007, 315, 1243-1249.	12.6	804
2	Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9023-9027.	7.1	494
3	Antisense oligonucleotides in therapy for neurodegenerative disorders. Advanced Drug Delivery Reviews, 2015, 87, 90-103.	13.7	243
4	Delivery of oligonucleotideâ€based therapeutics: challenges and opportunities. EMBO Molecular Medicine, 2021, 13, e13243.	6.9	181
5	Striosomes and mood dysfunction in Huntington's disease. Brain, 2007, 130, 206-221.	7.6	136
6	Delivery is key: lessons learnt from developing spliceâ€switching antisense therapies. EMBO Molecular Medicine, 2017, 9, 545-557.	6.9	119
7	Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias. Neurotherapeutics, 2019, 16, 263-286.	4.4	95
8	Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide. PLoS ONE, 2011, 6, e24308.	2.5	85
9	Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex. Human Molecular Genetics, 2017, 26, ddw395.	2.9	83
10	Huntingtonâ€™s disease biomarker progression profile identified by transcriptome sequencing in peripheral blood. European Journal of Human Genetics, 2015, 23, 1349-1356.	2.8	79
11	Iron loading is a prominent feature of activated microglia in Alzheimerâ€™s disease patients. Acta Neuropathologica Communications, 2021, 9, 27.	5.2	79
12	Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice. Molecular Therapy - Nucleic Acids, 2017, 8, 232-242.	5.1	78
13	Underlying molecular mechanisms ofDIO2susceptibility in symptomatic osteoarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1571-1579.	0.9	75
14	Exploring the Transcriptome of Ciliated Cells Using In Silico Dissection of Human Tissues. PLoS ONE, 2012, 7, e35618.	2.5	73
15	Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies. Molecular Neurobiology, 2014, 49, 1513-31.	4.0	72
16	Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease. BMC Molecular Biology, 2008, 9, 84.	3.0	66
17	Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon. Neurobiology of Disease, 2013, 58, 49-56.	4.4	66
18	Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA. BMC Genomics, 2012, 13, 28.	2.8	62

#	Article	IF	Citations
19	Elevated brain iron is independent from atrophy in Huntington's Disease. NeuroImage, 2012, 61, 558-564.	4.2	60
20	Deregulated Splicing Is a Major Mechanism of RNA-Induced Toxicity in Huntington's Disease. Journal of Molecular Biology, 2019, 431, 1869-1877.	4.2	57
21	Insoluble TATA-binding protein accumulation in Huntingtonâ€™s disease cortex. Molecular Brain Research, 2002, 109, 1-10.	2.3	54
22	Cellular composition of human glial cultures from adult biopsy brain tissue. Journal of Neuroscience Methods, 2007, 166, 89-98.	2.5	47
23	Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification. Nucleic Acid Therapeutics, 2014, 24, 4-12.	3.6	47
24	Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model. Molecular Neurodegeneration, 2018, 13, 31.	10.8	47
25	The IGF-I Amino-Terminal Tripeptide Glycine-Proline-Glutamate (GPE) Is Neuroprotective to Striatum in the Quinolinic Acid Lesion Animal Model of Huntington's Disease. Experimental Neurology, 1999, 159, 84-97.	4.1	45
26	Huntingtonâ€™s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 44849.	3.3	45
27	Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntingtonâ€™s disease peripheral blood samples. Metabolomics, 2016, 12, 137.	3.0	43
28	A 3 months mild functional test regime does not affect disease parameters in young mdx mice. Neuromuscular Disorders, 2010, 20, 273-280.	0.6	38
29	Huntingtin gene repeat size variations affect risk of lifetime depression. Translational Psychiatry, 2017, 7, 1277.	4.8	37
30	Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. Nucleic Acid Therapeutics, 2022, 32, 83-94.	3.6	35
31	Amyloid Î² in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Reviews in the Neurosciences, 2014, 25, 641-51.	2.9	34
32	Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients. Nucleic Acid Therapeutics, 2018, 28, 59-62.	3.6	33
33	Common disease signatures from gene expression analysis in Huntingtonâ€™s disease human blood and brain. Orphanet Journal of Rare Diseases, 2016, 11, 97.	2.7	32
34	Molecular investigation of TBP allele length:. Neurobiology of Disease, 2003, 13, 37-45.	4.4	31
35	Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3. Scientific Reports, 2016, 6, 35200.	3.3	31
36	Overview on Applications of Antisense-Mediated Exon Skipping. Methods in Molecular Biology, 2012, 867, 79-96.	0.9	30

#	Article	IF	Citations
37	Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntingtonâ€™s disease. Neuroscience, 2013, 238, 71-81.	2.3	26
38	Aggregate distribution in frontal and motor cortex in Huntington??s disease brain. NeuroReport, 2006, 17, 667-670.	1.2	25
39	Juvenileâ€Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review. Movement Disorders, 2022, 37, 16-24.	3.9	25
40	Iron accumulation induces oxidative stress, while depressing inflammatory polarization in human iPSC-derived microglia. Stem Cell Reports, 2022, 17, 1351-1365.	4.8	25
41	Intracerebroventricular Administration of a 2â€²-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain. Nucleic Acid Therapeutics, 2018, 28, 63-73.	3.6	23
42	Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease. Movement Disorders, 2019, 34, 1192-1202.	3.9	23
43	The dynamics of early-state transcriptional changes and aggregate formation in a Huntingtonâ€™s disease cell model. BMC Genomics, 2017, 18, 373.	2.8	22
44	TBP, a polyglutamine tract containing protein, accumulates in Alzheimer's disease. Molecular Brain Research, 2004, 125, 120-128.	2.3	21
45	In silico discovery and experimental validation of new proteinâ€“protein interactions. Proteomics, 2011, 11, 843-853.	2.2	20
46	Making (anti-) sense out of huntingtin levels in Huntington disease. Molecular Neurodegeneration, 2015, 10, 21.	10.8	20
47	Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain. Frontiers in Molecular Neuroscience, 2011, 4, 10.	2.9	19
48	Generation of 3 spinocerebellar ataxia type 1 (SCA1) patient-derived induced pluripotent stem cell lines LUMCi002-A, B, and C and 2 unaffected sibling control induced pluripotent stem cell lines LUMCi003-A and B. Stem Cell Research, 2018, 29, 125-128.	0.7	18
49	Selection and characterization of llama single domain antibodies against N-terminal huntingtin. Neurological Sciences, 2015, 36, 429-434.	1.9	16
50	TGFÎ² pathway deregulation and abnormal phosphoâ€SMAD2/3 staining in hereditary cerebral hemorrhage with amyloidosisâ€Dutch type. Brain Pathology, 2018, 28, 495-506.	4.1	15
51	Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset. Neurology: Genetics, 2018, 4, e275.	1.9	15
52	Osteopontin and phosphoâ€SMAD2/3 are associated with calcification of vessels in Dâ€CAA, an hereditary cerebral amyloid angiopathy. Brain Pathology, 2019, 29, 793-802.	4.1	15
53	Natriuretic Peptides in Post-mortem Brain Tissue and Cerebrospinal Fluid of Non-demented Humans and Alzheimerâ€™s Disease Patients. Frontiers in Neuroscience, 2018, 12, 864.	2.8	13
54	Brain Transcriptomic Analysis of Hereditary Cerebral Hemorrhage With Amyloidosis-Dutch Type. Frontiers in Aging Neuroscience, 2018, 10, 102.	3.4	13

#	Article	IF	Citations
55	Antisense-mediated isoform switching of steroid receptor coactivator-1 in the central nucleus of the amygdala of the mouse brain. BMC Neuroscience, 2013, 14, 5.	1.9	12
56	Age of onset in Huntingtonâ€™s disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes. Brain, 2017, 140, e42-e42.	7.6	11
57	Fetal porcine ventral mesencephalon graft. Determination of the optimal gestational age for implantation in Parkinsonian patients. Experimental Brain Research, 2000, 132, 345-350.	1.5	10
58	The immunohistochemical distribution of the GABA A receptor Î± 1 , Î± 2 , Î± 3 , Î² 2/3 and Î³ 2 subunits in the human thalamus. Journal of Chemical Neuroanatomy, 2017, 82, 39-55.	2.1	10
59	Co-expression Patterns between ATN1 and ATXN2 Coincide with Brain Regions Affected in Huntingtonâ€™s Disease. Frontiers in Molecular Neuroscience, 2017, 10, 399.	2.9	9
60	Pathological characterization of T2*-weighted MRI contrast in the striatum of Huntingtonâ€™s disease patients. NeuroImage: Clinical, 2020, 28, 102498.	2.7	9
61	Antisense Oligonucleotide-Induced Amyloid Precursor Protein Splicing Modulation as a Therapeutic Approach for Dutch-Type Cerebral Amyloid Angiopathy. Nucleic Acid Therapeutics, 2021, 31, 351-363.	3.6	8
62	Cost-effective HRMA pre-sequence typing of clone libraries; application to phage display selection. BMC Biotechnology, 2009, 9, 50.	3.3	7
63	Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias. Stem Cell Reviews and Reports, 2022, 18, 441-456.	3.8	7
64	The MID1 Protein: A Promising Therapeutic Target in Huntingtonâ€™s Disease. Frontiers in Genetics, 2021, 12, 761714.	2.3	7
65	Generation of genetically matched hiPSC lines from two mosaic facioscapulohumeral dystrophy type 1 patients. Stem Cell Research, 2019, 40, 101560.	0.7	6
66	Generation of 3 human induced pluripotent stem cell lines LUMCi005-A, B and C from a Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch type patient. Stem Cell Research, 2019, 34, 101359.	0.7	6
67	Neurotrophic requirements of rat embryonic catecholaminergic neurons from the rostral ventrolateral medulla. Developmental Brain Research, 1999, 116, 217-222.	1.7	4
68	Multidisciplinary Collaboration to Facilitate Hypotheses Generation in Huntington's Disease. , 2015, , .		3
69	Generation of 5 induced pluripotent stem cell lines, LUMCi007-A and B and LUMCi008-A, B and C, from 2 patients with Huntington disease. Stem Cell Research, 2019, 39, 101498.	0.7	3
70	Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections. Methods in Molecular Biology, 2022, 2434, 333-341.	0.9	3
71	CAG repeat size in the normal HTT allele and age of onset in Huntington's disease. Movement Disorders, 2011, 26, 2450-2451.	3.9	2
72	Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology. Stem Cell Research, 2020, 49, 102055.	0.7	2

#	Article	IF	Citations
73	Effect of post-mortem delay on N-terminal huntingtin protein fragments in human control and Huntington disease brain lysates. PLoS ONE, 2017, 12, e0178556.	2.5	2
74	I01â€…QRX-704, a novel antisense oligonucleotide therapy, designed to prevent hd pathology while maintaining htt function. , 2018, , .		1
75	Statistical method for modeling sequencing data from different technologies in longitudinal studies with application to Huntington disease. Biometrical Journal, 2021, 63, 745-760.	1.0	1
76	Huntington Disease Gene Expression Signatures in Blood Compared to Brain of YAC128 Mice as Candidates for Monitoring of Pathology. Molecular Neurobiology, 2022, 59, 2532-2551.	4.0	1
77	B16â€…Common disease signatures from gene expression analysis in huntingtonâ€™s disease human blood and brain. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A14.2-A15.	1.9	0
78	B17â€…Blood transcriptome replicates dysregulation found in human huntingtonâ€™s disease brain and shares an immune signature with alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A15.1-A15.	1.9	0
79	I8â€…Huntingtin gene repeat polymorphisms affect risk of lifetime depression in the general population. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A61.3-A62.	1.9	0
80	P2â€274: MAPPING OF NATRIURETIC PEPTIDES AND THEIR RECEPTORS IN THE BRAINS OF NONâ€DEMENTED HUMAN SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P782.	0.8	0
81	Ameliorating Huntington's Disease by Targeting Huntingtin mRNA. , 0, , .		0
82	A putative role for genome-wide epigenetic regulatory mechanisms in Huntingtonâ€™s disease: A computational assessment. F1000Research, 0, 6, 1888.	1.6	0
83	A07â€…A comparative study on blood and brain hd signatures: comparing mouse and human hd gene expression data. , 2018, , .		0
84	A33â€…Differences in bioenergetic status in patient-derived fibroblast cells are associated with age of onset in huntington disease. , 2018, , .		0